New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study

Table 2 Association between baseline serum indoxyl sulfate levels and clinical parameters

	Univariate		Multivariable
	B (95% CI)	P	B (95% CI)	P
Age (per 1 year increase)	0.003 (−0.004 to 0.01)	0.36	–
BMI (per 1 kg/m² increase)	− 0.014 (− 0.035 to 0.008)	0.22	–
SBP (per 1 mmHg increase)	0.004 (− 0.004 to 0.012)	0.31	–
eGFR (per 1 mL/min/1.73m² increase)	−0.015 (− 0.022 to − 0.008)	< 0.001	−0.013 (− 0.018 to0.001)	0.02
Log-transformed UPCR (per 1 increase)	0.028 (−0.050 to 0.107)	0.46	–
Hemoglobin (per 1 mg/dL increase)	−0.074 (− 0.123 to − 0.031)	0.001	−0.012 (− 0.059 to 0.034)	0.60
Phosphorus (per 1 mg/dL increase)	0.263 (0.130 to 0.391)	< 0.001	0.085 (−0.053 to 0.224)	0.22
Intact PTH (per 1 mg/dL increase)	0.002 (0.001 to 0.003)	< 0.001	0.001 (0.000 to 0.002)	0.05
serum albumin (per 1 g/dL increase)	−0.024 (− 0.183 to 0.135)	0.77	–

Abbreviation: BMI body mass index, SBP systolic blood pressure, eGFR estimated glomerular filtration rate, UPCR urine protein to creatinine ratio, PTH parathyroid hormone

ISSN: 1471-2369